SCHEMBL22263126

SCHEMBL22263126

Fc1ccc(CN2CN=C(SCc3ccccc3CSC3=NCN(Cc4ccc(F)c(F)c4)CN3)NC2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ KMT2A Q03164 3/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPK1 P28482 1/20 0.36
▸ CLPP Q16740 3/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ DRD4 P21917 1/20 0.34
▸ TP53 P04637 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19061872 0.91 MAPK1 (0.41) HTTALDH1A1TSHRCYP1A2CYP2D6
SCHEMBL20920185 0.90 CYP1A2 (0.42) HTTTSHRCYP1A2CYP2D6KMT2A
SCHEMBL22263119 0.86 ALDH1A1 (0.43) ALDH1A1TSHRCYP1A2CYP2D6KMT2A
SCHEMBL20918028 0.85 CYP1A2 (0.44) ALDH1A1TSHRCYP1A2CYP2D6KMT2A
SCHEMBL19019905 0.85 ALDH1A1 (0.40) HTTALDH1A1TSHRCYP1A2CYP2D6
SCHEMBL19061438 0.84 ALDH1A1 (0.43) HTTALDH1A1TSHRKMT2AMAPK1
SCHEMBL22263137 0.84 MAPK1 (0.50) ALDH1A1TSHRCYP1A2CYP2D6KMT2A
SCHEMBL19019925 0.82 TRPV6 (0.43) HTTALDH1A1CYP1A2CYP2D6LMNA
SCHEMBL19062037 0.82 METAP2 (0.43) ALDH1A1KMT2AMAPK1KDM4EMAPT
SCHEMBL22263088 0.82 CYP1A2 (0.42) TSHRCYP1A2CYP2D6KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092020-A1 IDO/TDO Inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-03-20 — — US disclosed
US-12209079-B2 IDO/TDO inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-01-28 — — US disclosed
US-20220380305-A1 IDO/TDO Inhibitor CANBAS CO., LTD. 2022-12-01 — — US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 — — US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209079-B2 IDO/TDO inhibitor IDO1, IDO2, TDO2 HTT 71/4885ALDH1A1 3331/4885TSHR 115/4885
US-20200239452-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 HTT 71/4885ALDH1A1 3331/4885TSHR 115/4885
US-20250092020-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 HTT 71/4885ALDH1A1 3331/4885TSHR 115/4885
US-20220380305-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 HTT 100/4885ALDH1A1 3591/4885TSHR 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback